


PHARMACEUTICAL 2019

AGILE THERAPEUTICS INC Rank 291 of 371









PHARMACEUTICAL 2019

AGILE THERAPEUTICS INC Rank 291 of 371



The relative strengths and weaknesses of AGILE THERAPEUTICS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of AGILE THERAPEUTICS INC compared to the market average is the variable Property and Equipment, increasing the Economic Capital Ratio by 755% points. The greatest weakness of AGILE THERAPEUTICS INC is the variable Net Income, reducing the Economic Capital Ratio by 307% points.

The company's Economic Capital Ratio, given in the ranking table, is -472%, being 141% points below the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	8,458
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	2,218
Liabilities, Non-Current	0
Other Assets	18
Other Compr. Net Income	0
Other Expenses	542
Other Liabilities	0
Other Net Income	-721
Property and Equipment	13,916
Research and Development	9,777
Revenues	0
Selling, General and Administrative Expense	8,739

Output Variable	Value in 1000 USD
Assets	22,392
Liabilities	2,218
Expenses	19,058
Stockholders Equity	20,174
Net Income	-19,779
Comprehensive Net Income	-19,779
Economic Capital Ratio	-472%

